undamentalytics Newsletter
Sign in

Elanco Animal Health Inc cash flow statement

In fiscal 2025, Elanco Animal Health Inc's operations generated $560m of cash; it spent $276m on capital projects, leaving free cash flow of $284m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations156174487224−41483452271541560617
Depreciation and amortisation254318296314517716682694662680400
Stock-based pay2025264947665946556872
Capital spending11099135140135159171140147276238
Free cash flow467535384−176324281131394284379
Free cash flow after stock pay255032735−22325822285339216307
Shares issued001,66001,2205004250———

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ELAN vs JAZZELAN vs OGNAMRX vs ELAN

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Elanco Animal Health Inc's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Elanco Animal Health Inc.